Expert meeting on paediatric development of fixed-dose combinations for the treatment of the human immunodeficiency virus (HIV)

Details


Title	Expert meeting on paediatric development of fixed-dose combinations for the treatment of the human immunodeficiency virus (HIV)
Date	10/11/2015 - 10/11/2015
Location	European Medicines Agency, London, UK
Summary	As a requirement of the Paediatric Regulation, all new medicinal products developed for the treatment of HIV-1 infection in adults, must have an agreed paediatric investigation plan (PIP) in place, ensuring the necessary data are obtained to support the medicine's authorisation for use in children, when appropriate. The Paediatric Committee (PDCO) is responsible for agreeing these PIPs. The purpose of this expert meeting is to advise the EMA and the PDCO on the best development pathways for fixed-dose combinations for the treatment of children and adolescents living with HIV.

Name	Language	First published
Agenda - Expert meeting on paediatric development of fix-dose combinations for treatment of HIV	(English only)	2015-09-29
Presentation - Meeting objectives	(English only)	2016-01-05
Presentation - Agreed PIPs for FDCs for the treatment of HIV-1 infection (Andrea Ecker)	(English only)	2016-01-05
Presentation - HIV and FDC: aspects of two guidelines (Filip Josephson)	(English only)	2016-01-05
Report of the expert meeting on paediatric development of fixed-dose combinations (FDCs) for the treatment of human immunodeficiency virus (HIV) infection	(English only)	2016-02-02